Journal of Clinical Research In HIV AIDS And Prevention

Journal of Clinical Research In HIV AIDS And Prevention

Journal of Clinical Research In HIV AIDS And Prevention – Aim And Scope

Open Access & Peer-Reviewed

Submit Manuscript

Aims & Scope

Journal of Clinical Research in HIV AIDS and Prevention publishes original research, systematic reviews, and clinical studies advancing the prevention, diagnosis, treatment, and management of HIV/AIDS and associated co-infections.
HIV Prevention Antiretroviral Therapy Viral Pathogenesis Vaccine Development Clinical Epidemiology
Scope Boundary: We focus on clinical research, epidemiology, and translational studies in HIV/AIDS. We do NOT consider basic immunology without HIV context, general infectious disease reviews, or purely social science studies without clinical outcomes.

Core Research Domains

Tier 1 Priority

HIV Prevention & Prophylaxis

  • Pre-exposure prophylaxis (PrEP) efficacy and adherence studies
  • Post-exposure prophylaxis (PEP) protocols and outcomes
  • Behavioral interventions and risk reduction strategies
  • Prevention of mother-to-child transmission (PMTCT)
  • Combination prevention approaches
  • Novel prevention technologies and microbicides
Typical fit: Randomized controlled trial evaluating long-acting injectable PrEP adherence in high-risk populations with viral load monitoring and behavioral assessments.
Tier 1 Priority

Antiretroviral Therapy & Treatment

  • Highly active antiretroviral therapy (HAART) regimens and outcomes
  • Drug resistance patterns and genotypic analysis
  • Treatment adherence and retention in care
  • Pharmacokinetics and drug interactions
  • Treatment-as-prevention (TasP) strategies
  • Novel antiretroviral agents and formulations
Typical fit: Longitudinal cohort study examining virologic suppression rates and emergence of drug resistance mutations in patients switching to integrase inhibitor-based regimens.
Tier 1 Priority

Viral Pathogenesis & Immunology

  • HIV replication mechanisms and viral dynamics
  • Immune activation and chronic inflammation
  • CD4+ T-cell depletion and immune reconstitution
  • Viral reservoirs and latency mechanisms
  • Host-pathogen interactions
  • Immune response to HIV infection
Typical fit: Mechanistic study investigating the role of immune checkpoint molecules in HIV reservoir persistence during suppressive antiretroviral therapy with immunological and virological endpoints.
Tier 1 Priority

Clinical Epidemiology & Diagnostics

  • HIV incidence and prevalence studies
  • Transmission dynamics and molecular epidemiology
  • Diagnostic testing strategies and algorithms
  • Viral load and CD4 count monitoring
  • Point-of-care testing technologies
  • Early detection and acute HIV infection
Typical fit: Population-based surveillance study using phylogenetic analysis to characterize HIV transmission networks and identify clusters for targeted intervention.

Secondary Focus Areas

Co-infections & Comorbidities

Tuberculosis-HIV co-infection, hepatitis B/C co-infection, sexually transmitted infections (syphilis, gonorrhea), opportunistic infections, and HIV-associated malignancies with clinical management strategies.

Vaccine Research

HIV vaccine development, immunogen design, clinical trial outcomes, correlates of protection, and novel vaccination strategies including therapeutic vaccines.

Cure Research

HIV eradication strategies, shock-and-kill approaches, gene therapy interventions, stem cell transplantation, and functional cure investigations with measurable clinical endpoints.

Special Populations

Pediatric HIV care, adolescent health, maternal health and pregnancy outcomes, aging with HIV, and population-specific treatment considerations with clinical data.

Neurological Complications

HIV-associated neurocognitive disorders (HAND), AIDS dementia complex, central nervous system manifestations, and neurological outcomes in treated patients.

Clinical Implementation Science

Healthcare delivery models, test-and-treat strategies, linkage to care, retention strategies, and implementation of evidence-based interventions with outcome measures.

Emerging Research Areas

Selective Consideration with Additional Review

Artificial intelligence in HIV diagnosis and treatment optimization
Machine learning for viral load prediction and adherence monitoring
Telemedicine and mHealth interventions with clinical outcomes
Precision medicine approaches and pharmacogenomics
Long-acting drug delivery systems and implantable devices
CRISPR and gene editing technologies for HIV treatment
Immunotherapy and broadly neutralizing antibodies
Big data analytics for epidemiological modeling
Note: Submissions in emerging areas undergo additional editorial review to ensure clinical relevance, methodological rigor, and alignment with journal scope. Purely theoretical or computational studies without clinical validation may be redirected.

Explicitly Out of Scope

We Do NOT Consider

  • General immunology without HIV context: Basic immune system studies, non-HIV viral immunology, or immunological research not directly related to HIV/AIDS pathogenesis or treatment.
  • Purely social science research: Sociological studies, anthropological investigations, or qualitative research without clinical outcomes, epidemiological data, or intervention effectiveness measures.
  • Health policy without clinical data: Policy analyses, healthcare economics, or health systems research lacking original clinical data, patient outcomes, or implementation science components.
  • Alternative medicine without rigorous trials: Complementary therapies, herbal remedies, or alternative treatments without randomized controlled trials, systematic reviews, or robust clinical evidence.
  • General infectious disease reviews: Broad infectious disease topics, non-HIV sexually transmitted infections as primary focus, or infectious disease research without HIV co-infection context.
  • Basic virology of non-HIV viruses: Studies of other retroviruses, general viral replication mechanisms, or virology research without direct HIV application or translational relevance.

Article Types & Editorial Priorities

Fast-Track Review

Priority 1 Articles

  • Original Research Articles (clinical trials, cohort studies, mechanistic studies)
  • Systematic Reviews and Meta-Analyses (PRISMA-compliant)
  • Clinical Practice Guidelines and Consensus Statements
  • Methods and Protocols (novel diagnostic or therapeutic approaches)
Standard Review

Priority 2 Articles

  • Short Communications (preliminary findings, pilot studies)
  • Data Notes (datasets, registries, surveillance data)
  • Perspectives and Commentaries (expert opinion on recent advances)
  • Case Series (minimum 5 cases with novel clinical insights)
Rarely Considered: Single case reports, opinion pieces without data, narrative reviews without systematic methodology, and letters to the editor are generally not accepted unless they present exceptional clinical significance or address urgent public health concerns.

Editorial Standards & Requirements

Reporting Guidelines

CONSORT for randomized trials, STROBE for observational studies, PRISMA for systematic reviews, ARRIVE for animal studies, and STARD for diagnostic accuracy studies.

Data Transparency

Authors must provide access to underlying data, statistical code, and study protocols. Clinical trial registration required (ClinicalTrials.gov, ISRCTN, or equivalent).

Ethics Approval

IRB/Ethics committee approval mandatory for human subjects research. Informed consent documentation required. Animal studies must follow institutional guidelines.

Preprint Policy

Preprints on recognized servers (medRxiv, bioRxiv) are acceptable. Authors must disclose preprint posting and update with publication details upon acceptance.